Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol for a Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, 12-week Treatment, Adaptive Proof-of-principle Study of Twice Daily Oral Dosing of a Novel PDE4 Inhibitor (ASP9831) in Subjects With Non-alcoholic Steatohepatitis (NASH)

NCT00668070 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00668070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00668070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol for a Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, 12-week Treatment, Adaptive Proof-of-principle Study of Twice Daily Oral Dosing of a Novel PDE4 Inhibitor (ASP9831) in Subjects With Non-alcoholic Steatohepatitis (NASH)
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
October 31, 2010
Enrollment
114 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic steatohepatitis